Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

Astellas and Pfizer announced that neoadjuvant plus adjuvant enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) ...

The FDA has granted full approval to rucaparib (Rubraca) for adults with BRCA-mutated metastatic castration-resistant prostate cancer. The decision is based on a confirmatory analysis of a randomized ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

Rucaparib received FDA approval for BRCA-mutated mCRPC after prior androgen receptor–directed therapy, based on the TRITON3 trial results. The trial demonstrated significant improvement in ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate ...